Table 2.

Assessment of the quality of life after anlotinib treatment by FKSI-15 and FKSI-DRS scoring.

Treatment	n	Assessment	Mean ± SD	Median	Range	p
Baseline	41	FKSI-15	49.41 ± 9.28	53	23–60	–
		FKSI-DRS	30.56 ± 5.08	32	17–36	–
Cycle 2	38	FKSI-15	50.53 ± 7.78	51.5	27–60	0.93
		FKSI-DRS	30.95 ± 4.81	31.5	15–36	0.97
Cycle 4	34	FKSI-15	49.15 ± 7.99	49.5	25–60	0.07
		FKSI-DRS	30.47 ± 4.42	31	16–36	0.18
Cycle 6	31	FKSI-15	49.48 ± 9.10	52	24–60	0.40
		FKSI-DRS	30.19 ± 5.50	32	13–36	0.26
Cycle 8	22	FKSI-15	52.14 ± 6.94	54	34–59	0.94
		FKSI-DRS	32.27 ± 3.77	33	22–36	0.87